Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 12, 2008, Pages 1269-1277

  Vardakas, Konstantinos Z ^a   Siempos, Ilias I ^a   Grammatikos, Alexandros ^a   Athanassa, Zoe ^a   Korbila, Ioanna P ^a   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; GEMIFLOXACIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE SEVERITY; HEADACHE; HOSPITAL ADMISSION; HUMAN; INSOMNIA; LIVER FUNCTION; LOBAR PNEUMONIA; MONOTHERAPY; MORTALITY; NAUSEA AND VOMITING; PATIENT ASSESSMENT; PHOTOSENSITIVITY; RASH; SIDE EFFECT; TREATMENT OUTCOME;

EID: 57349155272     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080358     Document Type: Article

References (67)

1. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. Arch Intern Med 1997;157:1709-18.
2. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the United Kingdom. Eur Respir J 1997;10:1530-4.
3. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37.
4. Rello J, Catalan M, Diaz E, et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002;28:1030-5.
5. Felmingham D, Canton R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007;55:111-8.
6. Menendez R, Torres A, Zalacain R, et al. Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-5.
7. Mandell LA, Wunderink RG, Anzueto A, et al.; Infectious Diseases Society of America. American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
8. Rosmarakis ES, Soteriades ES, Vergidis PI, et al. From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J 2005;19:673-80.
9. Falagas ME, Rosmarakis ES. Clinical decision-making based on findings presented in conference abstracts: Is it safe for our patients? Eur Heart J 2006;27:2038-9.
10. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13.
11. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
14. Carbon C, Ariza H, Rabie WJ, et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. Clin Microbiol Infect 1999;5:724-32.
15. D'Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005;49:4035-41.
16. Erard V, Lamy O, Bochud PY, et al. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2004;23:82-8.
17. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
18. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746-54.
19. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004;38(Suppl 1):S16-23.
20. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999;16:748-63.
21. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24:1292-308.
22. Geijo Martinez MP, Diaz de Tuesta Chow-Quan AM, Herranz CR, et al. Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization. Med Interna 2002;19:621-5.
23. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002;24:736-51.
24. Hoeffken G, Meyer HP, Winter J, et al.; Community-acquired Pneumonia Study Group. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553-64.
25. Kalbermatter V, Bagilet D, Diab M, et al. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization. Med Clin (Barc) 2000;115:561-3.
26. Katz E, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004;27:395-405.
27. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-20.
28. Lin TY, Lin SM, Chen HC, et al. An open label randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J 2007;30:321-32.
29. Lode H, File TM Jr, Mandell L, et al.; 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002;24:1915-36.
30. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998;30:397-404.
31. Petitpretz P, Arvis P, Marel M, et al.; CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-95.
32. Portier H, Brambilla C, Garre M, et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005;24:367-76.
33. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135-43.
34. Welte T, Petermann W, Schurmann D, et al.; MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005;41:1697-705.
35. Xu S, Xiong S, Xu Y, et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. J Huazhong Univ Sci Technolog Med Sci 2006;26:421-4.
36. Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004;3:329-36.
37. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993;148:1418-26.
38. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
39. Shorr AF, Susla GB, Kollef MH. Quinolones for treatment of nosocomial pneumonia: a meta-analysis. Clin Infect Dis 2005;40(Suppl 2):S115-22.
40. Falagas ME, Matthaiou DK, Vardakas KZ. Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2006;81:1553-66.
41. Siempos II, Vardakas KZ, Manta KG, et al. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007;29:548-60.
42. Matthaiou DK, Peppas G, Bliziotis IA, et al. Ciprofloxacin/metronidazole versus beta-lactam-based treatment of intra-abdominal infections: a meta-analysis of comparative trials. Int J Antimicrob Agents 2006;28:159-65.
43. Bliziotis IA, Michalopoulos A, Kasiakou SK, et al. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2005;80:1146-56.
44. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002;36:1938-43.
45. Shefet D, Robenshtock E, Paul M, et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Arch Intern Med 2005;165:1992-2000.
46. Querol-Ribelles JM, Tenias JM, Querol-Borras JM, et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005;25:75-83.
47. Lodise TP, Kwa A, Cosler L, et al. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007;51:3977-82.
48. Falagas ME, Siempos II, Bliziotis IA, et al. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin Proc 2006;81:1567-74.
49. Karlowsky JA, Thornsberry C, Critchley IA, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother 2003;47:1790-7.
50. Karlowsky JA, Thornsberry C, Jones ME, et al.; TRUST Surveillance Program. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003;36:963-70.
51. Morrissey I, Robbins M, Viljoen L, et al. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods. J Antimicrob Chemother 2005;55:200-8.
52. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from the PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008;7:1.
53. Adam HJ, Schurek KN, DeCorby MR, et al. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates. J Antimicrob Chemother 2006;58:202-4.
54. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: Have we begun to turn the corner on Rresistance to certain antimicrobial classes? Clin Infect Dis 2005;41:139-48.
55. Adam HJ, Schurek KN, Nichol KN, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother 2007;51:198-207.
56. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
57. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated in lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-95.
58. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-4.
59. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42.
60. Metersky ML, Ma A, Houck PM, et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007;131:466-73.
61. Vardakas KZ, Falagas ME. Interpreting the findings of a cohort study in bacteremic patients with community acquired pneumonia. Chest 2007;132:1715-6.
62. Kahn JB, Bahal N, Wiesinger BA, et al. Cumulative clinical trial experience with levofloxacin for patients with community-acquired pneumonia-associated pneumococcal bacteremia. Clin Infect Dis 2004;38(Suppl 1):S34-42.
63. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41:2256-60.
64. Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999;43:2793-7.
65. Siempos II, Vardakas KZ, Kopterides P, et al.Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008;62:661-8.
66. File TM Jr. Current challenges in the treatment of community-acquired pneumonia. Clin Infect Dis 2004;38(Suppl 1):S1-4.
67. Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007;120:783-90.